Evidence map›Paper›PMID 29506478›Full record

Trial reportBMC cancer2018

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.

Dae-Won Lee, Kyung-Hun Lee, Hee-Jun Kim, Tae-Yong Kim, Jin-Soo Kim, Sae-Won Han, Do-Youn Oh, Jee Hyun Kim, Seock-Ah Im, Tae-You Kim

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01429961 (Phase II Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01429961 phase2unknown statusnot on this map

Phase II Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma

TypeinterventionalSponsorSeoul National University HospitalRan2011 to 2013Enrolled38ConditionsAdvanced Hepatocellular CarcinomaArmsSOX
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Dae-Won Lee
Kyung-Hun LeeDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.
Hee-Jun KimDepartment of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Tae-Yong KimDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.
Jin-Soo KimDepartment of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, South Korea.
Sae-Won HanDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.
Do-Youn OhDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.
Jee Hyun KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Seock-Ah ImDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.
Tae-You KimDepartment of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea. kimty@snu.ac.kr.
Seoul National University Hospital · KRSNUH SMG-SNU Boramae Medical Center · KRChung-Ang University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicenter, open-label, single-arm phase II trial that evaluated the efficacy of S-1 and oxaliplatin (SOX) in advanced hepatocellular carcinoma. All patients included in the present study were systemic treatment-naïve. Prior treatment with sorafenib was allowed, but other treatments were not.

methodsPatients received S-1 (40 mg/m

resultsThirty six patients with advanced hepatocellular carcinoma were included in this study. The median TTP was 3.0 months (95% confidence interval (CI), 0.75-5.25), and the median OS was 10.3 months (95% CI, 6.4-14.3). Bone metastasis was associated with poorer TTP and OS. The efficacy of SOX was unaffected by prior sorafenib or locoregional therapy. The objective response rate was 13.9%. No grade 4 toxicity or death from adverse events occurred. The most common grade 3 toxicities were neutropenia (13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%).

conclusionsAlthough this trial did not meet its primary end point, the SOX regimen showed comparable efficacy and safety to the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen. As the SOX regimen is easier for patients, SOX may be a reasonable substitute for FOLFOX in hepatocellular carcinoma.

trial registrationClinicaltrials.gov NCT01429961 . Registered 7 September 2011.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCarcinoma, HepatocellularDrug CombinationsFemaleFollow-Up StudiesHumansLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinDrug CombinationsOrganoplatinum CompoundsOxaliplatinOxonic AcidS 1 (combination)TegafurChemotherapyHepatocellular carcinomaOxaliplatinPhase IIS-1

Identifiers

PMID29506478
PMCPMC5838934
OpenAlexW2794947073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.